ClinicalTrials.gg
RecruitingNCT06909110Updated Aug 14, 2025

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

A Phase 1/2 interventional study of Adenovirus Specific T- Lymphocytes and Cytomegalovirus Specific T-Lymphocytes in Adenovirus, Cytomegalovirus Infections and Epstein-Barr Virus Infections, sponsored by Jessie L. Alexander. Recruiting at 3 sites in United States. Open to participants aged 1 Month to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Jessie L. Alexander · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
1 Month to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Adenoviridae Infections with a site in United States — 17 open to participants now, 21 under way, 2 of them phase 3. Adenoviridae Infections · United States.

Planned enrollment
36th of 68
25 · median 27
Started
2025
with 2 others
Phase 1/2
14 of 78
4 open now
Primary completion
2029-05
later than 16 of 18 live
Registered
73rd of 78
by date

Among the 78 studies in Adenoviridae Infections with a site in United States, this one is the 36th largest by planned enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2025, is one of 14 in phase 1/2, reaches primary completion later than 16 of the 18 other live ones, and was the 73rd registered.

Adenoviridae Infections

136 studies on the registry are indexed under Adenoviridae Infections; 34 are open to participants now.

Browse Adenoviridae Infections studies →

Open to participants now

17 of the 78 studies in Adenoviridae Infections with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Adenoviridae Infections studies recruiting now, 9 (36%) set no upper age limit and 12 (48%) stop at 75 or younger; 17 take children under 18; 4 take healthy volunteers.

This study: 1 Month to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Adenoviridae Infections with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenovirus, CMV, and EBV, in subjects who have previously received any type of allogeneic HCT or solid organ transplant (SOT), or have compromised immunity. Reconstitution of anti-viral immunity by donor-derived cytotoxic T lymphocytes has shown promise in preventing and treating infections with adenovirus, CMV, and EBV. However, the weeks taken to prepare patient-specific products, and cost associated with products that may not be used limits their value. In this trial, we will evaluate viral specific T cells generated by gamma capture technology. Eligible patients will include HCT and/or SOT recipients, and/or patients with compromised immunity who have adenovirus, CMV, or EBV infection or refractory viremia that is persistent despite standard therapy. Infusion of the cellular product will be assessed for safety and efficacy.

Read the detailed description

If a subject shows a partial response, defined as a decrease in viral load of at least 50% from baseline or 50% improvement of clinical signs and symptoms, or no response, they are eligible to receive up to 4 additional cellular infusions from the same donor, at a minimum of 14-day intervals. If the same donor is no longer available, eligible, or appropriate, another donor may be considered for a maximum of 4 total cellular infusions at the discretion of the study PI and treating physician. A subject will not exceed a maximum of 5 total infusions from 2 donors.

Subjects are followed for 6 months post initial viral-specific T cell infusion. If subjects receive additional infusion(s), GvHD and adverse events will be followed for an additional 90 days from last infusion. Data may be abstracted from subjects' medical charts for an additional 1 year after most recent viral-specific T cell infusion.

03

Conditions studied

  • Adenovirus
  • Cytomegalovirus Infections
  • Epstein-Barr Virus Infections

Keywords

  • Cytokine Capture System
  • Adenovirus
  • Cytomegalovirus
  • Epstein-Barr Virus
  • Hematopoietic Cell Transplant
  • Solid Organ Transplant
04

Who can participate

Ages eligible
1 Month to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patient Inclusion Criteria

  1. Patient, parent, or legal guardian must have given written , according to FDA guidelines. For patients ≥ 7 years of age who are developmentally able, assent or affirmation will be obtained, if feasible.
  2. Male or female, 1 month through 65 years old, inclusive, at the time of informed consent.
  3. Prior hematopoietic stem cell transplant, AND/OR prior solid organ transplant (liver, kidney, lung and/or heart, intestinal, pancreatic, and/or multivisceral), AND/OR diagnosis of primary immunodeficiency AND/OR current/recent administration of therapy for cancer or disease.
  4. If receiving , must be able to taper dose to less than 1 mg/kg/day prednisone (or equivalent) prior to cellular infusion.
  5. Negative pregnancy test for females ≥10 years old or who have reached menarche, unless surgically sterilized or .
  6. Diagnosis of Adenovirus, CMV, or EBV infection, persistent despite standard therapy.

A. Adenovirus Infection or Disease (at minimum, one of the below sub-criteria must be met):

  1. Active adenovirus infection: (i.e. gastroenteritis, pneumonia, hemorrhagic cystitis, hepatitis, pancreatitis, meningitis) defined as the demonstration of adenovirus by specimen from affected site(s) (by culture or histology), or the detection of adenovirus by culture, PCR or direct fluorescent antibody stain in fluid in the presence of worsening or persistent clinical or imaging findings despite at least 14 days of appropriate antiviral therapy (i.e. cidofovir, brincidofovir, or other available pharmacological agents)
  2. adenoviremia: defined as DNAemia ≥1000 copies/mL or \<1 log decrease after at least 2 weeks of appropriate antiviral therapy (i.e. cidofovir, brincidofovir, or other available pharmacological agents)
  3. Intolerance of or to antiviral medications.

B. CMV Infection or Disease (at minimum, one of the below sub-criteria must be met):

  1. Active CMV infection: (i.e. pneumonia, meningitis, retinitis, hepatitis, hemorrhagic cystitis, and/or gastroenteritis) defined as the demonstration of CMV by biopsy specimen from affected site(s) (by culture or histology) or the detection of CMV by culture, PCR or direct fluorescent antibody stain in fluid in the presence of worsening or persistent clinical or imaging findings despite at least 14 days of appropriate antiviral therapy (i.e. Foscarnet, ganciclovir, cidofovir, or other available pharmacological agents)
  2. Refractory CMV viremia: defined as the continued presence of DNAemia, with ≥1,000 IU/mL or \<1 log decrease after at least 14 days of appropriate antiviral therapy (i.e. Foscarnet, ganciclovir, cidofovir, or other available pharmacological agents)
  3. Intolerance of or contraindication to antiviral medications.

C. EBV Infection or Disease (at minimum, one of the below sub-criteria must be met):

  1. EBV DNAemia ≥1000 IU/mL, persistent despite 2 doses of rituximab,
  2. Biopsy proven lymphoma or lymphoproliferative disease with EBV genomes detected in tumor cells by immunocytochemistry (i.e. EBER positive) or in situ PCR,
  3. Clinical or imaging findings consistent with EBV lymphoma or lymphoproliferation with current or recent elevated EBV viral load in peripheral blood in a patient where biopsy is deemed too high risk,
  4. Failure of antiviral therapy, as determined by one of the two bullets below after two weeks of anti-CD20 targeted therapy such as rituximab, i. There was an increase or less than 50% response at sites of lymphoma disease or lymphoproliferation.

    ii. There was a rise or a fall of less than 50% in EBV viral load in peripheral blood.

  5. Intolerance or contraindication to rituximab.

Patient Exclusion Criteria:

  1. Received ATG or Alemtuzumab within 21 days of viral-specific T cell infusion and a lack of evidence of T cell survival, defined by \<10 CD3+ T cells/uL (in unique situations, plasmapheresis may be considered).
  2. Active acute grades II-IV.
  3. Active severe chronic GVHD.
  4. Received donor lymphocyte infusion, with the exception of a fraction of an umbilical cord blood, within 21 days of planned viral-specific T cell infusion. Subjects receiving a fraction of an umbilical cord blood within 21 days of the viral-specific T cell infusion will not be excluded.
  5. Active and uncontrolled relapse of (other than EBV+ post-transplant lymphoproliferative disorder or lymphoma).
  6. Anticipated initiation of new lymphotoxic therapy within 4 weeks of viral-specific T cell infusion.
  7. Patients who are pregnant or lactating.
  8. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, or concomitant medications, which, in the opinion of the investigator, may pose additional risks to participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study.

Donor Inclusion Criteria

  1. Age ≥ 12*
  2. Able to understand and sign the consent/assent to the procedure
  3. Partial (2/6 or more) HLA match to the recipient
  4. A pediatric donor could be selected as a donor only if a suitable adult donor is not available (as attested by the research team) or is ineligible according to FACT requirements. For pediatric donors:

    • Related to the recipient
    • Apheresis does not need a blood prime before the procedure
    • Adequate peripheral venous access
    • Explicit evaluation of the donors' willingness to donate cells, as attested by the research team
    • Must have understanding that they are helping their ill relative, as attested by the research team
    • Will gain emotional/psychological benefit from their ability to help and want to donate for a relative, as attested by the research team
    • Inclusion of minor donors that are not relatives of the recipient will need to be evaluated on a case-by-case basis for the IRB to evaluate the potential benefit to these participants (whether they will receive an emotional and psychological boost from helping the recipient) *If the only suitable donor is less than 12 years old, a single patient exception to this inclusion criteria will be submitted and approved by the IRB before obtaining the donor's assent and their LAR consent.

Donor Exclusion Criteria

  1. Donor is pregnant
  2. Donor is positive
  3. Donor is positive for and/or
  4. Deemed to be a high-risk donor based on responses to donor risk questionnaire
  5. Deemed high risk due to preexisting medical condition or abnormal lab results
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Viral Specific T-Lymphocytes

    Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS® Plus where they will be stimulated in vitro with viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system. By this method, viral specific, gamma-secreting T cells, are captured in a closed, sterile system.

    Biological: Adenovirus Specific T- Lymphocytes · Biological: Cytomegalovirus Specific T-Lymphocytes · Biological: Epstein-Barr Virus Specific T-Lymphocytes

Interventions

  • BiologicalAdenovirus Specific T- Lymphocytes

    Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.

  • BiologicalCytomegalovirus Specific T-Lymphocytes

    Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Cytomegalovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.

  • BiologicalEpstein-Barr Virus Specific T-Lymphocytes

    Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Epstein-Barr viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.

06

What researchers measure

Primary outcomes

  1. Grade III-IV Acute Graft versus host disease

    The number of patients who develop Grade III-IV acute graft versus host disease (GVHD) attributed to the viral specific T cells.

    Time frame: Day 0 through 90 days after last cellular infusion

  2. CTCAE Grade 4/5 Adverse Events

    The incidence of patients who develop CTCAE Grade 4/5 Adverse events related to infusion

    Time frame: Day 0 through 30 days from last cellular infusion

Secondary outcomes

  1. Number of patients achieving 6-month survival (dichotomous)

    Time frame: First cellular infusion to 6 months post first cellular infusion

  2. Viral load by Polymerase Chain Reaction (PCR)

    The pace at which the viral load is undetectable in whole blood or plasma

    Time frame: Baseline and 14 days, 1 month, 3 months, and 6 months after cellular infusion

  3. Viral load from Respiratory Viral Panel (RVP)

    The pace at which the viral load is undetectable from nasopharyngeal swab

    Time frame: Baseline and 14 days, 1 month, 3 months, and 6 months after cellular infusion

  4. Viral load from Bronchoalveolar lavage (BAL)

    The pace at which the viral load is undetectable from bronchial washing

    Time frame: Baseline and 14 days, 1 month, 3 months, and 6 months after cellular infusion

  5. Viral load from Urine

    The pace at which the viral load is undetectable from urine sample

    Time frame: Baseline and 14 days, 1 month, 3 months, and 6 months after cellular infusion

  6. Viral load from Stool

    The pace at which the viral load is undetectable from stool sample

    Time frame: Baseline and 14 days, 1 month, 3 months, and 6 months after cellular infusion

  7. Viral load from fluid/tissue

    The pace at which the viral load is undetectable from other fluid/tissue sample

    Time frame: Baseline and 14 days, 1 month, 3 months, and 6 months after cellular infusion

  8. Clinical response to viral specific infusion

    By imaging and symptomatology

    Time frame: Baseline and 14 days, 1 month, 3 months, and 6 months after cellular infusion

  9. Number of patient who require antiviral agents

    The introduction of concomitant antiviral medication post infusion, e.g. cidofovir for adenovirus, foscarnet for CMV, rituximab for EBV

    Time frame: Baseline and 14 days, 1 month, 3 months, and 6 months after cellular infusion

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for May 2029, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
Apr 3, 2025
StartActual
Apr 30, 2025
Primary completionEst.
May 1, 2029
CompletionEst.
Jan 1, 2032
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06909110
Lead sponsor
Jessie L. Alexander
Responsible party
Jessie L. Alexander (Clinical Associate Professor of Pediatrics, Stanford University) — Sponsor-investigator
First posted
Apr 3, 2025
Start date
Apr 30, 2025
Primary completion
May 1, 2029 (estimated)
Completion
Jan 1, 2032 (estimated)
Last update
Aug 14, 2025

Study contacts

Jessie Alexander, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion